Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
69
TEVA Quote, Financials, Valuation and Earnings
Last price:
$28.40
Seasonality move
:
10.36%
Day range:
$27.96 - $28.46
52-week range:
$12.47 - $27.90
Dividend yield:
0%
P/E ratio:
45.38x
P/S ratio:
1.90x
P/B ratio:
4.40x
Volume:
13.7M
Avg. volume:
12.8M
1-year change:
59.61%
Market cap:
$31.9B
Revenue:
$16.6B
EPS (TTM):
$0.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$4.3B | $0.67 | 3.94% | 71.31% | $27.90 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.56% | 309.55% | $324.25 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $3.50 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
NVO
Novo Nordisk A/S
|
$11.9B | $0.66 | -1.21% | 0.25% | $53.28 |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$27.83 | $27.90 | $31.9B | 45.38x | $0.00 | 0% | 1.90x |
|
AMGN
Amgen, Inc.
|
$340.16 | $324.25 | $183.2B | 26.30x | $2.38 | 2.8% | 5.13x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.34 | $3.50 | $5.3M | -- | $0.00 | 0% | 1.89x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NVO
Novo Nordisk A/S
|
$47.99 | $53.28 | $213.2B | 13.98x | $0.58 | 3.6% | 4.58x |
|
PHGE
BiomX, Inc.
|
$4.77 | $399.00 | $7.3M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
70.19% | -0.313 | 73.66% | 0.53x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
NVO
Novo Nordisk A/S
|
37.33% | 1.647 | 6.46% | 0.46x |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$2.3B | $1.1B | 2.75% | 10.27% | 23.84% | -$53M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
NVO
Novo Nordisk A/S
|
$8.9B | $3.7B | 41.85% | 68.76% | 31.74% | $4.8B |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
Teva Pharmaceutical Industries Ltd. vs. Competitors
-
Which has Higher Returns TEVA or AMGN?
Amgen, Inc. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of 33.55%. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About TEVA or AMGN?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $27.90, signalling upside risk potential of 0.24%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -4.68%. Given that Teva Pharmaceutical Industries Ltd. has higher upside potential than Amgen, Inc., analysts believe Teva Pharmaceutical Industries Ltd. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 1 0 AMGNAmgen, Inc.10 15 2 -
Is TEVA or AMGN More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock TEVA or AMGN?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.8% to investors and pays a quarterly dividend of $2.38 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or AMGN?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Teva Pharmaceutical Industries Ltd.'s net income of $436M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 45.38x while Amgen, Inc.'s PE ratio is 26.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 1.90x versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.1.90x 45.38x $4.5B $436M AMGNAmgen, Inc.5.13x 26.30x $9.6B $3.2B
-
Which has Higher Returns TEVA or CANF?
Can-Fite BioPharma Ltd. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of --. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About TEVA or CANF?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $27.90, signalling upside risk potential of 0.24%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $3.50 which suggests that it could grow by 932.45%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 1 0 CANFCan-Fite BioPharma Ltd.2 0 0 -
Is TEVA or CANF More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock TEVA or CANF?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or CANF?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Teva Pharmaceutical Industries Ltd.'s net income of $436M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 45.38x while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 1.90x versus 1.89x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.1.90x 45.38x $4.5B $436M CANFCan-Fite BioPharma Ltd.1.89x -- -- --
-
Which has Higher Returns TEVA or NSRX?
Nasus Pharma has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of --. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B NSRXNasus Pharma-- -- -- -
What do Analysts Say About TEVA or NSRX?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $27.90, signalling upside risk potential of 0.24%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Teva Pharmaceutical Industries Ltd. has higher upside potential than Nasus Pharma, analysts believe Teva Pharmaceutical Industries Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 1 0 NSRXNasus Pharma0 0 0 -
Is TEVA or NSRX More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TEVA or NSRX?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or NSRX?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are larger than Nasus Pharma quarterly revenues of --. Teva Pharmaceutical Industries Ltd.'s net income of $436M is higher than Nasus Pharma's net income of --. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 45.38x while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 1.90x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.1.90x 45.38x $4.5B $436M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns TEVA or NVO?
Novo Nordisk A/S has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of 26.68%. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat Novo Nordisk A/S's return on equity of 68.76%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B NVONovo Nordisk A/S76.12% $0.70 $42.7B -
What do Analysts Say About TEVA or NVO?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $27.90, signalling upside risk potential of 0.24%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.28 which suggests that it could grow by 11.03%. Given that Novo Nordisk A/S has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Novo Nordisk A/S is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 1 0 NVONovo Nordisk A/S6 3 2 -
Is TEVA or NVO More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.
-
Which is a Better Dividend Stock TEVA or NVO?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.6% to investors and pays a quarterly dividend of $0.58 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TEVA or NVO?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Teva Pharmaceutical Industries Ltd.'s net income of $436M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 45.38x while Novo Nordisk A/S's PE ratio is 13.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 1.90x versus 4.58x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.1.90x 45.38x $4.5B $436M NVONovo Nordisk A/S4.58x 13.98x $11.7B $3.1B
-
Which has Higher Returns TEVA or PHGE?
BiomX, Inc. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of --. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About TEVA or PHGE?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $27.90, signalling upside risk potential of 0.24%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8264.78%. Given that BiomX, Inc. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe BiomX, Inc. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 1 0 PHGEBiomX, Inc.1 0 0 -
Is TEVA or PHGE More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock TEVA or PHGE?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or PHGE?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are larger than BiomX, Inc. quarterly revenues of --. Teva Pharmaceutical Industries Ltd.'s net income of $436M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 45.38x while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 1.90x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.1.90x 45.38x $4.5B $436M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
